3 December, 2024AAVantgarde Bio announces FDA Orphan Drug Designation for AAVB-081 for the treatment of Usher Syndrome type 1B Retinitis Pigmentosa
26 November, 2024Handbook for impact accountability in VC developed by coalition of impact-driven funds
28 October, 2024AAVantgarde Founder and CSO is elected as President of the European Society of Gene and Cell Therapy (ESGCT)
25 September, 2024Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic